FDA approval: Varenicline Tartrate

AI Summary

The FDA approved a generic varenicline tartrate formulation (0.5 mg and 1 mg tablets) via ANDA 219382 on 6 July 2026. This is a regulatory action that permits the manufacture and distribution of the product; it does not present new clinical trial results or safety data.

Plain-language summary

FDA approval of a generic varenicline tartrate formulation; regulatory action rather than clinical evidence of efficacy or safety.

Study design

As stated by the source record.

Reported figures

Quoted from the source exactly as published.

Clinical bottom line

This approval permits use of a generic alternative to brand-name varenicline. Clinical professionals should be aware that ANDA approval is based on bioequivalence to an approved reference product, not de novo efficacy or safety trials; the clinical profile mirrors that of the innovator formulation.

Caveats

• This regulatory record does not contain clinical trial results, efficacy data, or safety outcomes.
• ANDA approval is predicated on bioequivalence; no new safety or efficacy data are reported.
• The record does not specify the reference listed drug or provide comparative bioavailability parameters.
• No adverse event profile or post-market surveillance data are included in this record.

Evidence assessment

Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.

Follow from this

Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.